TRANSIENT CRANIAL NEUROPATHY IN PROSTATIC-CANCER WITH BONE METASTASESAFTER RHENIUM-186-HEDP TREATMENT

Rhenium-186 (tin) hydroxyethylidene diphosphonate (Re-186-HEDP), a bon e-seeking radiopharmaceutical, has been successfully used in the treat ment of patients with painful bone metastases. Toxicity is usually lim ited to reversible thrombocytopenia. An infrequent but clinically sign ificant side effect is the occurrence of transient cranial neuropathy, We report on two prostatic cancer patients with metastatic bone cance r. Both patients developed transient cranial neuropathy shortly after treatment with Re-186-HEDP. Transient neuropathy of cranial nerves nee ds to be distinguished from neurological abnormalities caused by disea se progression.